Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Infusion Timing in Postoperative HCC
NCT07243691Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: 2-year Recurrence-Free Survival Rate. Started Dec 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07243691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243691.